Dec 012024
Drug Name |
Active Ingredient(s) |
Approval Date |
FDA-Approved Use on Approval Date |
Press Release |
Drug Trials Snapshot |
| Iomervu | iomeprol | 11/27/2024 | For use as a radiographic contrast agent | ||
| Rapiblyk | landiolol | 11/22/2024 | To treat supraventricular tachycardia | ||
| Attruby | acoramidis | 11/22/2024 | To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis | ||
| Ziihera | zanidatamab-hrii | 11/20/2024 | To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer | ||
| Revuforj | revumenib | 11/15/2024 | To treat relapsed or refractory acute leukemia |
Sorry, the comment form is closed at this time.